All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention AlpE, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention BV100, all published on March 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about BV100
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention AlpE, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention BV100, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering BV100. Shared-story counts are live from our verified record — not editorial picks.
BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.
BV100 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.